VX 5
Alternative Names: Anti-CXCL13 antibody; Anti-CXCL13 monoclonal antibody; VX-5; VX5/5261; VX5/5261-muIgLatest Information Update: 28 Apr 2025
At a glance
- Originator Vaccinex
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Chemokine CXCL13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Encephalomyelitis
- No development reported Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Intraperitoneal)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Cancer in USA (Intraperitoneal)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Intraperitoneal)